Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mCRPC treated with olaparib | mCRPC patients who receive olaparib in daily clinical practice |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Olaparib | Drug | Olaparib given according the clinical practice to BRCA positive mCRPC patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| disease control | projected survival from treatment start | From the date of treatment start until the date of last follow-up or date of death from any cause, whichever came first, assessed up to 120 months |
| Measure | Description | Time Frame |
|---|---|---|
| biochemical response | rate of patients with PSA reduction > 50% | Through study completion, an average of 1 years |
| response rate | rate of patients with measurable disease showing partial or complete response |
Not provided
Inclusion Criteria:
BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice
Exclusion Criteria:
Olaparib treatment in a clinical trial
Not provided
Not provided
Not provided
Not provided
BRCA mutant Metastatic castration-resistant prostate cancer patients progressing after first-line ARPI who are treated with olaparib in clinical practice
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Orazio Caffo, MD | Contact | +390461902478 | orazio.caffo@apss.tn.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sabrina Rossetti | Recruiting | Naples | Italy |
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C531550 | olaparib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Through study completion, an average of 1 years |
| PFS | projected survival without progression | From the date of treatment start until the date of first progression or date of death from any cause, whichever came first, assessed up to 120 months |
| toxicity rate | toxicity recorded during the treatment | Through study completion, an average of 1 years |
| Orazio Caffo | Recruiting | Trento | Italy |
|
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |